The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy by unknown
Vashi et al. Nutrition Journal 2013, 12:118
http://www.nutritionj.com/content/12/1/118RESEARCH Open AccessThe relationship between baseline nutritional
status with subsequent parenteral nutrition and
clinical outcomes in cancer patients undergoing
hyperthermic intraperitoneal chemotherapy
Pankaj G Vashi1, Digant Gupta1,2*, Carolyn A Lammersfeld1, Donald P Braun1, Brenten Popiel1, Subhasis Misra1
and Komen C Brown1Abstract
Background: The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) is a promising treatment option for selected patients with peritoneal carcinomatosis. This retrospective
study investigated the relationship between baseline nutritional assessment with subsequent parenteral nutritional
(PN) and clinical outcomes in cancer patients undergoing CRS and HIPEC.
Methods: A consecutive series of 60 patients undergoing CRS and HIPEC at our institution between January 2009
and May 2011. Subjective Global Assessment (SGA) was used to assess nutritional status. Patients were classified
preoperatively as: well nourished (SGA-A), mildly-moderately malnourished (SGA-B), and severely malnourished
(SGA-C). For PN, patients were divided into 2 groups: those who received PN (PN+) and those who did not receive
PN (PN-). The primary outcomes of interest were length of stay (LOS), postoperative complications, ECOG
performance status (PS) and survival. LOS was calculated as the number of days in the hospital post surgery.
Performance status was measured on a scale of 0-4. Survival was calculated from the date of first visit to the date of
death/last contact.
Results: Of 60 patients, 19 were males and 41 females. The mean age at presentation was 50.3 years. The most
common cancer types were colorectal (n = 24) and gynecologic (n = 19) with the majority of patients (n = 47)
treated previously before coming to our institution. 33 patients were SGA-A, 22 SGA-B and 5 SGA-C prior to surgery.
Of a total of 60 patients, 31 received PN. Mean LOS for the entire cohort was 16.2 days (SD = 9.8). Mean LOS for
preoperative SGA-A, SGA-B and SGA-C were 15.0, 15.2 and 27.8 days respectively (ANOVA p = 0.02). Overall
incidence of complications was 26.7% (16/60). Complications were recorded in 9 of 33 (27.3%) preoperative
SGA-A patients and 7 of 27 (25.9%) SGA-B + C patients (p = 0.91). The median overall survival was 17.5 months
(95% CI = 13.0 to 22.1 months). Median survival for preoperative SGA-A and SGA-B + C cohorts was 22.4 and
10.4 months respectively (p = 0.006).
Conclusions: The preoperative SGA predicts LOS and survival in cancer patients undergoing HIPEC. Future
randomized clinical trials in this patient population should investigate the systematic provision of PN to all
malnourished patients in the preoperative period for a minimum of 7-10 days with the continuation of PN in the
postoperative period.* Correspondence: digant.gupta@ctca-hope.com
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Cytoreductive surgery (CRS) and hyperthermic intraperi-
toneal chemotherapy (HIPEC) as a combined treatment
modality is a promising therapeutic option for selected
patients with peritoneal carcinomatosis arising from dif-
ferent malignancies such as colorectal cancer, gastric
cancer, ovarian cancer or peritoneal mesotheliomas [1].
Numerous studies with different levels of evidence have
demonstrated a survival advantage in patients treated
with CRS and HIPEC as compared to those treated with
systemic chemotherapy alone [2-7]. However, the sur-
vival advantage often comes at the expense of significant
morbidity, which has been reported at a rate of 25% to
41% and can primarily be divided into surgery-related
and chemotherapy-related complications. Common
surgery-related complications are postoperative ileus,
anastomotic leakage, wound infection, bleeding, intra-
abdominal abscess, deep vein thrombosis and lung
embolism while the different cytostatic agents used for
HIPEC can lead to leucopenia, anemia, thrombopenia,
heart, liver or renal toxicity and other side effects [1,8].
These morbidities are often associated with a negative
impact on patients’ nutritional status and quality of
life [9-11].
While there are no data available on the prevalence of
malnutrition in patients with peritoneal carcinomatosis,
malnutrition is observed in up to 67% of patients with
ovarian cancer [12] and up to 80% of patients with
advanced colorectal cancer [13], the two most common
cancers associated with the development of peritoneal
carcinomatosis. Moreover, there is enough evidence in
the literature documenting the association of malnu-
trition with longer hospital stay, reduced response,
increased complications to anticancer therapy, increased
overall cost of care, and poor survival and quality of life
[13-19]. As a result, it has been recommended that
nutritional screening be performed in all peritoneal
carcinomatosis patients who are potential candidates for
CRS and HIPEC, while a more in-depth nutritional
assessment followed by adequate nutritional intervention
be considered in malnourished patients [10]. However,
there are no data available in the literature on the role of
nutritional assessment and support in peritoneal carci-
nomatosis patients undergoing CRS and HIPEC.
The aim of this study was to investigate the relationship
between baseline nutritional assessment with subsequent
parenteral nutritional (PN) and clinical outcomes in can-
cer patients undergoing CRS and HIPEC.
Methods
Study population
This was a retrospective study performed on a consecutive
case series of 60 cancer patients treated with R0/R1 CRS
and HIPEC at Cancer Treatment Centers of America®(CTCA) at Midwestern Regional Medical Center (MRMC)
between January 2009 and May 2011. Only patients with a
histologically confirmed diagnosis of cancer were inclu-
ded. The study did not restrict patients with respect to
treatment history, tumor histology or stage. This study
was approved by the Institutional Review Board at
Midwestern Regional Medical Center (MRMC).
CRS and HIPEC
After opening the abdomen, the presence of macroscopic
tumor deposits was recorded in 13 abdominopelvic
regions namely central abdomen, right upper quadrant,
epigastrium, left upper quadrant, left flank, left lower
quadrant, pelvis, right lower quadrant, right flank, upper
jejunum, lower jejunum, upper ileum and lower ileum
[20]. This leads to the calculation of a peritoneal car-
cinomatosis index (PCI) score [21] which standardizes the
reporting of tumor burden in patients with carcino-
matosis. The PCI is an assessment combining lesion size
(0–3) with tumor distribution to quantify the extent of
disease as a numeric score. The score was calculated at
the time of surgical exploration of the abdomen and
pelvis. The PCI is of great value in the process of deciding
between a surgically aggressive complete cytoreduction
and a palliative debulking procedure [21].
After CRS, the patient was then prepared for HIPEC.
Catheters were placed, one in each subdiaphragmatic
space for outflow catheter and connected to a Y-
connector and brought out through the midline incision.
The inflow catheter was placed down in the pelvis and was
similarly connected to a Y-connector, and then brought out
in the cephalad portion of the midline incision. Tempera-
ture probes were placed in each anterior abdominal wall,
and also brought out through the midline incision. The
midline incision was closed by using a running #1 Prolene
in a baseball stitch fashion. The catheters were then
hooked up to the perfusion circuit. The abdominal cavity
was instilled with 3 liters of crystalloid solution and per-
fused with warming, until a temperature of 41 degrees
Celsius was achieved. At this time, assessment was done to
make sure there were no leaks noted from the abdominal
cavity. 30 mg of Mitomycin-C was then added into the per-
fusion circuit for perfusion of the abdomen. The patient
was perfused for a total of 60 minutes with an average flow
of approximately to 1700 to 2000 mL per minute. The
temperature was between 41 to 42 degrees Celsius, as
monitored by the temperature probe with an inflow
temperature of 43 degrees Celsius. After these 60 minutes
of perfusion, an additional 10 mg of Mitomycin-C was
added into the perfusion circuit and the patient was per-
fused for an additional 30 minutes. At the completion of
the 90 minute perfusion, the perfusate was flushed and the
abdomen was additionally flushed with 3 liters of crystal-
loid solution, following which the flushed solution was
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reopened and the remaining portion of the surgery was
completed.
Nutritional status assessment
All patients in this study were scheduled for a consultation
with a dietitian. Prior to each consultation, a dietitian
reviewed the patient’s history from the medical record and
verified the patient’s current weight. Subjective Global
Assessment (SGA) was used to assess nutritional status.
The SGA is a clinical technique that combines data from
subjective and objective aspects of medical history (weight
change, dietary intake change, gastrointestinal symptoms,
and changes in functional capacity) and physical examin-
ation (loss of subcutaneous fat, muscle wasting, ankle or
sacral edema and ascites). After evaluation, patients are
categorized into three distinct classes of nutritional status;
well nourished (SGA-A), moderately malnourished (SGA-
B) and severely malnourished (SGA-C) as described by
Detsky et al [22]. The SGA has been validated in a number
of diverse patient populations, including cancer patients
[23-27]. It has also been correlated with a number of
objective nutritional assessment indicators, morbidity,
mortality, and QoL measures [28-31]. At the subjects’
first visit, measurement of height and weight were
performed. The subjects wore light clothing and no
shoes. BMI was calculated as weight (kg) / squared
height (m2).
Parenteral nutrition
PN was administered as per American Society of
Parenteral and Enteral Nutrition (ASPEN) guidelines
[32]. Total daily calories given were 25-30 kcal/kg for
BMI <30 and 22-25 kcal/kg of ideal body weight if
BMI >30. Proteins were given at 2 g/kg for BMI < 30
and 2.5 g/kg of ideal body weight if BMI > 30. Calo-
ries from lipids were limited to < 30% of total daily
requirement. The decision to consider PN in our pa-
tients depended on two major factors – preoperative
SGA status and presence or absence of bowel obs-
truction. PN was recommended for all patients with
preoperative SGA-C. All patients with bowel obstruct-
ive symptoms, irrespective of their SGA status were
considered for PN.
The patients were monitored closely for their nutri-
tional status and recovery of the gastrointestinal func-
tions after CRS/ HIPEC. PN was initiated in those
patients who had delayed gastric function recovery or
who had multiple bowel resections. Nutrition and
Metabolic Support Team (NSMT) followed all the
patients and initiated PN within 7 days after the surgery
when indicated. Many patients were discharged with
PN which was discontinued only when adequate oral
intake was established.Statistical analysis
Nutritional status (as measured by SGA) and PN were
the primary independent variables of interest. SGA was
used as a categorical variable (SGA-A, SGA-B and SGA-C).
For PN, patients were divided into 2 groups: those
who received PN (PN+) and those who did not re-
ceive PN (PN-).
The primary outcomes of interest were length of stay
(LOS), postoperative complications, ECOG performance
status and survival. LOS was calculated as the number
of days patients stayed in the hospital post surgery. Post-
operative complications were judged by the attending
surgical oncologist and gastroenterologist and defined as
any clinical event not typically seen in patients who
receive HIPEC. Performance status was measured on a
scale of 0-4. Survival was defined as the time interval
between the date of first visit to our hospital and the
date of patient’s death from any cause or the date of last
contact/last known to be alive. Patients alive at the time
of this analysis (June 2013) were considered censored
for the purpose of this analysis.
Mean LOS was compared across the 3 SGA groups
and 2 PN groups using Analysis of Variance (ANOVA)
and independent sample t-test respectively. Incidence of
complications was compared across the SGA and PN
groups using chi-square tests. The survival was esti-
mated using the Kaplan-Meier method and tested with
the log-rank test across the SGA and PN groups. All
data were analyzed using IBM SPSS version 20.0 (IBM,
Armonk, NY, USA). All analyses were two-tailed, and a
difference was considered to be statistically significant if
the p value was less than or equal to 0.05.
Results
Baseline characteristics
Table 1 describes the baseline characteristics of our
patient cohort. Of a total of 60 patients, 31 received PN.
Of those 31 patients, 23 received postoperative PN while
8 received PN both pre- and postoperatively. The aver-
age duration of preoperative PN was 5.1 days while that
of postoperative PN was 27.4 days. Thirteen patients
were analytic (newly diagnosed and treated at our insti-
tution) while 47 patients were non-analytic (previously
treated elsewhere prior to coming to our institution).
At the time of this analysis (June 2013), 38 (63.3%) pa-
tients had expired. The mean follow-up time duration
was 15.1 months with a range of 1.9 to 37.8 months.
Table 2 compares the patient characteristics between
the PN + and PN- groups. As compared to the PN-
group, the PN + group had a greater proportion of male
patients as well as a greater proportion of patients with
previously treated disease, gynecologic cancers and
malnourished status prior to surgery. There were no
statistically significant differences in the mean PCI score
Table 1 Baseline patient characteristics (N = 60)
Characteristic Categories Number Percent
(%)






Range 21.4 – 69.1








Treatment history Analytic 13 21.7
Non-analytic 47 78.3
Preoperative SGA A 33 55
B 22 36.7
C 5 8.3
PN No 29 48.3
Yes 31 51.7
Table 2 Baseline characteristics of PN+ and PN- groups
Characteristic PN- (n = 29) PN+ (n = 31) P-value
Gender
Males 5 (17.2%) 14 (45.2%) 0.02
Females 24 (82.8%) 17 (54.8%)




Colorectal 11 (37.9%) 13 (41.9%) 0.91
Gynecologic 8 (27.5%) 11 (35.4%)
Appendix 5 (17.2%) 3 (9.7%)
Peritoneal 3 (10.3%) 2 (6.5%)
Others 2 (6.9%) 2 (6.5%)
Treatment history
Analytic 8 (27.6%) 5 (16.1%) 0.28
Non-analytic 21 (72.4%) 26 (83.9%)
Preoperative SGA
A 20 (69%) 13 (41.9%) 0.10
B 7 (24.1%) 15 (48.4%)
C 2 (6.9%) 3 (9.7%)
Mean PCI score 17.2 20.4 0.17
Length of CRS and HIPEC
(minutes)
662 673 0.82
Values in parenthesis are column percentages.
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2 PN groups. There were a total of 4 peritonectomies, 1 in
the PN- group and 3 in the PN + group (p = 0.33). The
total number of anastomoses/resections in the PN- and
PN+ groups was 30 and 35 respectively. The median was
1 in both the groups (p = 0.93).LOS
Mean LOS for the entire study population was 16.2 days
(standard deviation = 9.8). The mean LOS for patients in
the pre-operative SGA-C group was significantly longer
than the mean LOS for those in the SGA-A and SGA-B
groups as shown in Table 3. Similarly, the mean LOS for
patients in the PN + group was significantly longer than
the mean LOS for patients in the PN- group.Perioperative morbidity
There were a total of 4 readmissions within 30 days of
discharge, 1 in the PN- group and 3 in the PN + group
(p = 0.33). The reasons for readmissions were pelvic ab-
scess and wound infection with fistula in the PN- group
and copious discharge per rectum, abdominal pain, and
wound dehiscence in the PN + group. Only one patient
expired within 30 days of surgery in the PN + group,
whereas there were no deaths within 30 days of surgery
in the PN- group.Complications
Overall incidence of complications was 26.7% (16/60).
Nine patients had 1 complication, two patients had 2, 3
and 4 complications each and 1 patient had 10 complica-
tions. The number of complications was correlated to
LOS (Pearson r = 0.3, p = 0.03). Complications were recor-
ded in 9 of 33 (27.3%) pre-operative SGA-A patients and
7 of 27 (25.9%) SGA-B + C patients (chi-square p = 0.91).
Similarly, complications were recorded in 4 of 29 (13.8%)
PN- patients and 12 of 31 (38.7%) PN + patients (chi-
square p = 0.03). Most common were wound-related
complications and sepsis.Table 3 Mean LOS across preoperative SGA and PN groups




• Well nourished (n = 33) 15.0 ANOVA
• Moderately malnourished (n = 22) 15.2 p = 0.02
• Severely malnourished (n = 5) 27.8
PN
• No (n = 29) 12.7 2 sample t-test
• Yes (n = 31) 19.4 p = 0.007
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The median overall survival for the entire patient cohort
was 17.5 months (95% CI = 13.0 to 22.1 months).
Figure 1 shows the survival curves for the 2 categories of
preoperative SGA. Well nourished patients had a me-
dian survival of 22.4 months (95% CI: 18.7 to 26.1),
while malnourished patients had a median survival of
10.4 months (95% CI: 5.2 to 15.7); the difference being
statistically significant (log rank p = 0.006).
Figure 2 shows the survival curves for the 2 PN
groups. Patients in the PN + group had a median survival
of 14.3 months (95% CI: 9.9 to 18.8), while patients in
the PN- group had a median survival of 22.4 months
(95% CI: 12.6 to 32.2); the difference being statistically
significant (log rank p = 0.01).
Subgroup analysis by SGA
We conducted a subgroup analysis to compare the out-
comes (LOS, survival and post-operative complications)
between the PN + and PN- groups in preoperative SGA-
A patients only. No statistically significant differences
were found between the two PN groups with regard to
any of the outcomes.
SGA and ECOG status
For the entire population (n = 60), the mean preoperative
and postoperative SGA scores were 4.4 and 5.7 respect-
ively, while the corresponding PS scores were 1.3 andFigure 1 Survival stratified by 2 categories of preoperative SGA. Each
group. Vertical lines indicate censored patients, i.e., those who reached the1.6 respectively, p < 0.05 for both. In the PN + group
(n = 31), the mean preoperative and postoperative
SGA (5.1 and 6.6) and PS (1.5 and 1.9) scores were not
significantly different; p > 0.05 for both. In the PN- group
(n = 29), preoperative and postoperative SGA scores were
not significantly different but postoperative PS score (1.4)
was significantly worse than the preoperative PS score
(1.1); p = 0.001.
Discussion
Cancer patients are particularly susceptible to nutritional
depletion due to the combined effects of the malignant
disease and its treatment. CRS followed by HIPEC is a
major surgical procedure that can further accentuate the
risk of nutritional depletion in patients with peritoneal
carcinomatosis [10,11,33]. As a result, timely nutritional
assessment and intervention in this patient population
might be critical to achieving optimal clinical outcomes
including LOS, cost, quality of life, survival and ability to
tolerate treatment. In this retrospective study of the first
60 patients at our institution who had CRS and HIPEC
for peritoneal carcinomatosis, we investigated the rela-
tionship between baseline nutritional status and clinical
outcomes. We also conducted a preliminary analysis of
clinical outcomes as a function of parenteral nutrition.
There are 2 key findings of our study. Baseline nutri-
tional status, as evaluated using SGA, was predictive of
patient LOS. This finding is consistent with the existingdrop in a probability curve indicates one or more events in that
end of their follow-up without experiencing death.
Figure 2 Survival stratified by 2 PN groups. Each drop in a probability curve indicates one or more events in that group. Vertical lines indicate
censored patients, i.e., those who reached the end of their follow-up without experiencing death.
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review (based on a total of 21 studies ) on the role of nu-
tritional status in predicting LOS in cancer concluded
that validated nutritional tools such as SGA are good
predictors of LOS in gastrointestinal cancers requiring
surgery [34]. Since CRS and HIPEC are associated with
significant morbidity which can potentially increase the
LOS, it is prudent to provide nutrition support during
the perioperative period in these individuals. It makes
sense to implement the ASPEN guidelines [32] for these
patients, which include nutritional screening, assessment,
and intervention as appropriate. Correcting malnutrition
may decrease the LOS and perhaps even reduce the rate
of hospital readmissions in this population. Consistent
with the vast body of existing literature in this area
[14,15], we also found that baseline nutritional status, as
evaluated using SGA, was a significant predictor of sur-
vival in this patient population.
The LOS in patients who received PN was longer than
in patients who did not receive PN. Similarly, the survival
in the PN+ group was shorter than in the PN- group. This
was expected considering the patients who did not receive
PN had regained gastrointestinal functions within 7 days
of surgery and were better nourished than patients who
received PN. Given the lack of comparability between thePN+ and PN- groups, no conclusions related to causation
can be drawn from these findings.
The peritoneal malignancy program at our institution
was started by a dedicated team of physicians, nurses
and surgical staff and led by a surgical oncologist with
special training in CRS and HIPEC. Our experience with
the first 60 patient in this study has helped us develop
processes for nutritional evaluation and interventions
with oral, parenteral or enteral nutrition in the pre- and
post-operative periods. Guidelines established by ASPEN
for nutritional support in surgical patients were used for
all patients [32]. Although the role of nutritional support
has not been studied in patients undergoing CRS and
HIPEC, the benefits of perioperative nutrition have been
well-established for other planned major abdominal
surgeries [35]. As part of future research in this area, the
role of additional pre-operative enteral nutrition to
enhance nutritional status in eligible cohorts could be
examined.
Some limitations of this study need to be acknow-
ledged. Our study, because of its retrospective nature,
relies on data not collected to test a specific hypothesis.
A majority of our patients had advanced stage disease at
presentation and had failed primary treatment elsewhere
before coming to our hospital. As a result, we acknowledge
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patients with peritoneal carcinomatosis, an issue that needs
to be tested in suitable patient populations. Our retrospect-
ive study was not designed to investigate a causative rela-
tionship between PN and clinical outcomes. This is evident
by the fact that our PN + and PN- groups were substa-
ntially different from each other with regard to the baseline
clinical and demographic characteristics. As compared to
the PN- group, the PN + group had a greater proportion of
male patients as well as a greater proportion of patients
with previously treated disease, gynecologic cancers and
malnourished status prior to surgery. As a result, no
definitive conclusions can be made regarding the role of
parenteral nutrition in improving clinical outcomes in this
patient population. Prospective randomized clinical trials
are needed to this effect. Our study had a relatively small
sample size of 60 patients. Finally, an overall complication
rate of 26.7% could be an underestimate owing to the
retrospective nature of this study and the lack of com-
plication grading criteria. Despite these limitations, to
the best of our knowledge, this is the first study to
evaluate the prognostic significance of nutritional as-
sessment in peritoneal carcinomatosis patients under-
going CRS and HIPEC.
Conclusions
The preoperative SGA predicts LOS and survival in can-
cer patients undergoing HIPEC. Future randomized clin-
ical trials in this patient population should investigate the
systematic provision of PN to all malnourished patients in
the preoperative period for a minimum of 7-10 days with
the continuation of PN in the postoperative period.
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